Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Hochheim Am Main – page 5

1 444 clinical trials in Hochheim Am Main, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Hochheim Am Main at a glance
1 444
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 444 trials in Hochheim Am Main

Open in trial search

Colorectal cancer metastatic

Recruiting

A Study of Ivonescimab Combined with Fluorouracil, Folinic Acid, and Oxaliplatin Compared to Bevacizumab for Patients with Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Summit Therapeutics Inc.

Vitiligo

Recruiting

Study of ruxolitinib cream for children aged 6 to 12 years with non-segmental vitiligo

Investigational
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Ruxolitinib
  • Sponsor:Incyte Corp.

Psoriasis

Recruiting

Study of deucravacitinib compared to placebo in adolescents aged 12-17 years with moderate to severe plaque psoriasis

Investigational
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Deucravacitinib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Chronic obstructive pulmonary disease

Recruiting

Study of AZD6793 tablets to reduce flare-ups in adults with moderate to very severe chronic obstructive pulmonary disease (COPD)

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD6793
  • Sponsor:Astrazeneca AB

Vitiligo+2

Recruiting

Long-term safety study of oral povorcitinib in patients with hidradenitis suppurativa, prurigo nodularis, or vitiligo who previously participated in clinical trials

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Povorcitinib
  • Sponsor:Incyte Corp.

Schizophrenia

Recruiting

Study of evenamide as add-on treatment for patients with treatment-resistant schizophrenia not adequately controlled by current antipsychotic medications

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Evenamide
  • Sponsor:Newron Pharmaceuticals S.p.A.

Dermatitis atopic

Recruiting

Long-term safety and effectiveness study of APG777 injection in patients with moderate-to-severe atopic dermatitis who previously received APG777 treatment

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:APG777
  • Sponsor:Apogee Therapeutics Inc.

Cardiovascular disorder+2

Recruiting

Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim Espana S.A.

Gastrointestinal carcinoma

Recruiting

Study of GSK5764227 alone and in combination for patients with previously treated advanced gastrointestinal tumors that cannot be removed by surgery or have spread

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:GSK5764227
  • Sponsor:Glaxosmithkline Research & Development Limited

Arteriosclerosis

Recruiting

Study of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Laroprovstat
  • Sponsor:Astrazeneca AB

Bronchiectasis

Recruiting

Study of BI 1291583 tablets taken once daily for 76 weeks in adults with bronchiectasis

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:BI 1291583
  • Sponsor:Boehringer Ingelheim Espana S.A.

Cardiac failure

Recruiting

Evaluating the Effect of Vicadrostat and Empagliflozin Combination Compared to Empagliflozin Alone in Patients with Heart Failure and Reduced Left Ventricular Function

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim International GmbH

Other cities in Germany

The busiest research cities in the country

All 506 cities in Germany

Clinical research in Hochheim Am Main

What the registry says about research in the country

01 Rare Genetic Disorders

Innovative research focusing on Gaucher disease and Niemann-Pick disease, exploring new therapeutic approaches for these challenging genetic conditions. Studies aim to evaluate novel treatments for improving neurological symptoms and overall patient outcomes.

  • Gaucher Disease TYPE 3 Treatment
  • Niemann-Pick Disease Management
  • Genetic Disease Therapies

Clinical investigations evaluating venglustat and nizubaglustat's effectiveness in managing disease progression.

02 Lysosomal Storage Disorders

Research centered on treating Mucopolysaccharidosis Type II (Hunter Syndrome) and Pompe disease, with multiple studies investigating innovative enzyme replacement therapies and novel drug combinations.

  • Hunter Syndrome Treatment
  • Infantile-onset Pompe Disease
  • Late-onset Pompe Disease

Evaluation of treatments like JR-141 and cipaglucosidase alfa for improved patient outcomes.

03 Respiratory Diseases

Studies focused on preventing respiratory syncytial virus infections in older adults, with particular attention to vaccine development and immune response assessment.

  • RSV Prevention
  • Vaccine Development
  • Immune Response Studies

Investigation of revaccination strategies and long-term protection against respiratory infections.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.